## SEQUENCE LISTING

<110> KUFER, PETER LENKKERI-SCHUTZ, ULLA LUTTERBUSE, RALF KOHLEISEN, BIRGIT
<120> LESS IMMUNOGENIC BINDING MOLECULES
<130> 028622-0155
<140> 10/588,734 <141> 2006-08-08
<150> PCT/EP05/001573 <151> 2005-02-16
<150> EP 04003445.6 <151> 2004-02-16
<160> 40
<170> PatentIn version 3.3
<210> 1 <211> 318 <212> DNA <213> Artificial Sequence
<220> <223> Description of Artificial Sequence: Synthetic OKT3 light chain
<pre>&lt;400&gt; 1 gacatccaga tgacccagtc tccatcctcc ctgtctgcat ctgtaggaga cagagtcacc atcacttgca gtgcaagttc aagcgtaagc tacatgaatt ggtatcagca gacaccaggg aaagccccta agagatggat ctatgacaca tccaaattgg cttctggggt cccatcaagg ttcagtggca gtggatctgg gacagattac actttcacca tcagcagtct gcaacctgaa gatattgcaa cttactactg tcaacagtgg agtagtaacc cttttacttt tggccagggg accaagctgc agatcacc</pre> 60 120 318
<210> 2 <211> 106 <212> PRT <213> Artificial Sequence
<220> <223> Description of Artificial Sequence: Synthetic OKT3 VL
<400> 2 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15
Asp Arg Val Thr Ile Thr Cys Ser Ala Ser Ser Ser Val Ser Tyr Met 20 25 30

Asn Trp Tyr Gln Gln Thr Pro Gly Lys Ala Pro Lys Arg Trp Ile Tyr 35 Asp Thr Ser Lys Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly Ser 50 55 Gly Ser Gly Thr Asp Tyr Thr Phe Thr Ile Ser Ser Leu Gln Pro Glu 70 75 Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Trp Ser Ser Asn Pro Phe Thr Phe Gly Gln Gly Thr Lys Leu Gln Ile Thr <210> 3 <211> 30 <212> DNA <213> Artificial Sequence <223> Description of Artificial Sequence: Synthetic oligonucleotide <400> 3 agagcaagtt caagcgtaag ctacatgaat <210> 4 <211> 10 <212> PRT <213> Artificial Sequence <223> Description of Artificial Sequence: Synthetic peptide <400> 4 Arg Ala Ser Ser Ser Val Ser Tyr Met Asn 5 <210> 5 <211> 21 <212> DNA <213> Artificial Sequence

<223> Description of Artificial Sequence: Synthetic

<220>

peptide

30

```
<400> 5
gacacatcca aagtggcttc t
                                                                       21
<210> 6
<211> 7
<212> PRT
<213> Artificial Sequence
<223> Description of Artificial Sequence: Synthetic
     peptide
<400> 6
Asp Thr Ser Lys Val Ala Ser
<210> 7
<211> 27
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: Synthetic
     oligonucleotide
<400> 7
                                                                       27
caacagtgga gtagtaaccc tctcact
<210> 8
<211> 9
<212> PRT
<213> Artificial Sequence
<223> Description of Artificial Sequence: Synthetic
     peptide
<400> 8
Gln Gln Trp Ser Ser Asn Pro Leu Thr
<210> 9
<211> 318
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: Synthetic
     CD3 VL
<400> 9
                                                                       60
gacatccaga tgacccagtc tccatcctcc ctgtctgcat ctgtaggaga cagagtcacc
atcacttgca gagcaagttc aagcgtaagc tacatgaatt ggtatcagca gacaccaggg
                                                                      120
aaagcccta agagatggat ctatgacaca tccaaagtgg cttctggggt cccatcaagg
                                                                      180
```

ttcagtggca gtggatctgg gacagattac actttcacca tcagcagtct gcaacctgaa 240 300 gatattgcaa cttactactg tcaacagtgg agtagtaacc ctctcacttt tggccagggg accaagctgc agatcacc 318 <210> 10 <211> 106 <212> PRT <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Synthetic CD3 VL <400> 10 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Ser Ser Val Ser Tyr Met 25 Asn Trp Tyr Gln Gln Thr Pro Gly Lys Ala Pro Lys Arg Trp Ile Tyr 35 40 45 Asp Thr Ser Lys Val Ala Ser Gly Val Pro Ser Arg Phe Ser Gly Ser 50 55 Gly Ser Gly Thr Asp Tyr Thr Phe Thr Ile Ser Ser Leu Gln Pro Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Trp Ser Ser Asn Pro Leu Thr 90 8.5 Phe Gly Gln Gly Thr Lys Leu Gln Ile Thr 100 <210> 11 <211> 357 <212> DNA <213> Artificial Sequence <223> Description of Artificial Sequence: Synthetic CD3 VH <400> 11 caggtgcagc tggtgcagtc tgggggaggc gtggtccagc ctgggaggtc cctgagactc 60 tcctgtaagt cttctggata caccttcact aggtatacga tgcactgggt ccgccaggct 120 ccagggaagg ggctggagtg gattggatac ataaatccta gccgtggtta tactaattat 180 240 aatcagaagg tgaaggaccg attcaccatc tccagagaca actccaagaa cacggccttt ctgcaaatgg acagcctgag acccgaggac acgggtgtgt atttctgtgc gagatattat 300

gatgatcatt actgccttga ctactggggc cagggcaccc cggtcaccgt ctcctca 357

<210> 12 <211> 11 <212> PR <213> Ar	9 .T	cial	. Sec	luenc	e										
<220> <223> De	scri 3 VH	•	n of	Art	ific	cial	Sequ	ience	e: Sy	nthe	etic				
<400> 12 Gln Val 1		Leu	Val 5	Gln	Ser	Gly	Gly	Gly 10	Val	Val	Gln	Pro	Gly 15	Arg	
Ser Leu	Arg	Leu 20	Ser	Cys	Lys	Ser	Ser 25	Gly	Tyr	Thr	Phe	Thr 30	Arg	Tyr	
Thr Met	His 35	Trp	Val	Arg	Gln	Ala 40	Pro	Gly	Lys	Gly	Leu 45	Glu	Trp	Ile	
Gly Tyr 50	Ile	Asn	Pro	Ser	Arg 55	Gly	Tyr	Thr	Asn	Tyr 60	Asn	Gln	Lys	Val	
Lys Asp 65	Arg	Phe	Thr	Ile 70	Ser	Arg	Asp	Asn	Ser 75	Lys	Asn	Thr	Ala	Phe 80	
Leu Gln	Met	Asp	Ser 85	Leu	Arg	Pro	Glu	Asp 90	Thr	Gly	Val	Tyr	Phe 95	Cys	
Ala Arg	Tyr	Tyr 100	Asp	Asp	His	Tyr	Cys 105	Leu	Asp	Tyr	Trp	Gly 110	Gln	Gly	
Thr Pro	Val 115	Thr	Val	Ser	Ser										
<210> 13 <211> 729 <212> DNA <213> Artificial Sequence															
<220> <223> Description of Artificial Sequence: Synthetic CD3 VH-VL															
<400> 13 caggtgcagc tggtgcagtc tgggggaggc gtggtccagc ctgggaggtc cctgagactc 60 tcctgtaagt cttctggata caccttcact aggtatacga tgcactgggt ccgccaggct 120 ccagggaagg ggctggagtg gattggatac ataaatccta gccgtggtta tactaattat 180															

aatcagaagg	tgaaggaccg	attcaccatc	tccagagaca	actccaagaa	cacggccttt	240
ctgcaaatgg	acagcctgag	acccgaggac	acgggtgtgt	atttctgtgc	gagatattat	300
gatgatcatt	actgccttga	ctattggggc	cagggcaccc	cggtcaccgt	ctcctcagtc	360
gaaggtggaa	gtggaggttc	tggtggaagt	ggaggttcag	gtggagtgga	cgacatccag	420
atgacccagt	ctccatcctc	cctgtctgca	tctgtaggag	acagagtcac	catcacttgc	480
agagcaagtt	caagcgtaag	ctacatgaat	tggtatcagc	agacaccagg	gaaagcccct	540
aagagatgga	tctatgacac	atccaaagtg	gcttctgggg	tcccatcaag	gttcagtggc	600
agtggatctg	ggacagatta	cactttcacc	atcagcagtc	tgcaacctga	agatattgca	660
acttactact	gtcaacagtg	gagtagtaac	cctctcactt	ttggccaggg	gaccaagctg	720
cagatcacc	•					729

<210> 14

<211> 243

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic CD3 VH-VL  $\,$ 

<400> 14

Gln Val Gln Leu Val Gln Ser Gly Gly Gly Val Val Gln Pro Gly Arg 1 5 10 15

Ser Leu Arg Leu Ser Cys Lys Ser Ser Gly Tyr Thr Phe Thr Arg Tyr 20 25 30

Thr Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile 35 40 45

Gly Tyr Ile Asn Pro Ser Arg Gly Tyr Thr Asn Tyr Asn Gln Lys Val50 55 60

Lys Asp Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Ala Phe 65 70 75 80

Leu Gln Met Asp Ser Leu Arg Pro Glu Asp Thr Gly Val Tyr Phe Cys 85 90 95

Ala Arg Tyr Tyr Asp Asp His Tyr Cys Leu Asp Tyr Trp Gly Gln Gly
100 105 110

Thr Pro Val Thr Val Ser Ser Val Glu Gly Gly Ser Gly Gly Ser Gly 115 120 125

Gly Ser Gly Gly Ser Gly Gly Val Asp Asp Ile Gln Met Thr Gln Ser  $130 \\ \hspace{1.5cm} 135 \\ \hspace{1.5cm} 140$ 

Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys 145 150 155 Arg Ala Ser Ser Ser Val Ser Tyr Met Asn Trp Tyr Gln Gln Thr Pro 165 170 Gly Lys Ala Pro Lys Arg Trp Ile Tyr Asp Thr Ser Lys Val Ala Ser 180 185 Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Thr Phe Thr Ile Ser Ser Leu Gln Pro Glu Asp Ile Ala Thr Tyr Tyr Cys 210 215 Gln Gln Trp Ser Ser Asn Pro Leu Thr Phe Gly Gln Gly Thr Lys Leu 225 230 235 Gln Ile Thr <210> 15 <211> 372 <212> DNA <213> Artificial Sequence <223> Description of Artificial Sequence: Synthetic CD19 VH <400> 15 caggtgcagc tgcagcagtc tggggctgag ctggtgaggc ctgggtcctc agtgaagatt 60 tcctqcaaqq cttctqqcta tqcattcaqt aqctactqqa tqaactqqqt qaaqcaqaqq 120 180 cctggacagg gtcttgagtg gattggacag atttggcctg gagatggtga tactaactac aatggaaagt tcaagggtaa agccactctg actgcagacg aatcctccag cacagcctac 240 atgcaactca gcagcctagc atctgaggac tctgcggtct atttctgtgc aagacgggag 300 actacgacgg taggccgtta ttactatgct atggactact ggggccaagg gaccacggtc 360 accgtctcct cc 372 <210> 16 <211> 124 <212> PRT <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Synthetic

CD19 VH

	)> 16 Val		Leu	Gln 5	Gln	Ser	Gly	Ala	Glu 10	Leu	Val	Arg	Pro	Gly 15	Ser		
Ser	Val	Lys	Ile 20	Ser	Cys	Lys	Ala	Ser 25	Gly	Tyr	Ala	Phe	Ser 30	Ser	Tyr		
Trp	Met	Asn 35	Trp	Val	Lys	Gln	Arg 40	Pro	Gly	Gln	Gly	Leu 45	Glu	Trp	Ile		
Gly	Gln 50	Ile	Trp	Pro	Gly	Asp 55	Gly	Asp	Thr	Asn	Tyr 60	Asn	Gly	Lys	Phe		
Lys 65	Gly	Lys	Ala	Thr	Leu 70	Thr	Ala	Asp	Glu	Ser 75	Ser	Ser	Thr	Ala	Tyr 80		
Met	Gln	Leu	Ser	Ser 85	Leu	Ala	Ser	Glu	Asp 90	Ser	Ala	Val	Tyr	Phe 95	Cys		
Ala	Arg	Arg	Glu 100	Thr	Thr	Thr	Val	Gly 105	Arg	Tyr	Tyr	Tyr	Ala 110	Met	Asp		
Tyr	Trp	Gly 115	Gln	Gly	Thr	Thr	Val 120	Thr	Val	Ser	Ser						
<213 <212	0> 17 l> 33 2> Di 3> As	33 NA	icial	L Sec	quenc	e e											
<220 <220	3> De	escr: 019 V	-	on of	f Art	cific	cial	Sequ	ıence	e: Sy	ynthe	etic					
gata atci caad ggga ccto	cctocagai atcco gtgga	ago d gca a tto d cac d aga a	aggco cagga ccago aggto	cage acago gttta ggato	ca aa cc ac ag to	agtgt cccaa ggcaa gcaa	tgat acto gtggg cctat	t tai	gato catco cggga ctgto	ggtg catg acag	ataq atgo actt	gttat catco ccaco	caa f	gaact tctac caaca	gccacc tggtac gtttct atccat ccgtgg	1 1 2 3	60 20 80 40 00 33
<21 C	1> 18	3															

. .

<210> 18 <211> 111 <212> PRT <213> Artificial Sequence <220>

<223> Description of Artificial Sequence: Synthetic CD19  $\rm VL$ 

<400> 18

Asp Ile Gln Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Leu Gly 1 5 10 15

Gln Arg Ala Thr Ile Ser Cys Lys Ala Ser Gln Ser Val Asp Tyr Asp 20 25 30

Gly Asp Ser Tyr Leu Asn Trp Tyr Gln Gln Ile Pro Gly Gln Pro Pro 35 40 45

Lys Leu Leu Ile Tyr Asp Ala Ser Asn Leu Val Ser Gly Ile Pro Pro 50 55 60

Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Asn Ile His 65 70 75 80

Pro Val Glu Lys Val Asp Ala Ala Thr Tyr His Cys Gln Gln Ser Thr 85 90 95

Glu Asp Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys

<210> 19

<211> 1504

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic anti-CD3

<400> 19

tgtacactcc gatatccagc tgacccagtc tccagcttct ttggctgtg ctctagggca 60 gagggccacc atctctgca aggccagcca aagtgttgat tatgatggtg atagttattt 120 gaactggtac caacagattc caggacagcc acccaaactc ctcatctatg atgcatccaa 180 tctagtttct gggatccac ccaggtttag tggcagtggg tctgggacag accttcacct 240 caacatccat cctgtggaga aggtggatgc tgcaacctat cactgtcagc aaagtactga 300 ggatccgtgg acgttcggtg gagggaccaa gctcgagatc aaaggtggtg gtggttctgg 360 cggcggcggc tccggtggtg gtggttctca ggtgcagctg cagcagtctg gggctgagct 420 ggtgaggcct gggtcctcag tgaagattc ctgcaaggct tctggctatg cattcagtag 480 ctactggatg aactgggtga agcagaggcc tggacagggc tcagcagtga ctaactaga tggacaggat ctaggatga ccactctgac 600 tgcagacgaa tcctccagca cagcctacat gcaactcagc agcctagat ctgaggactc ctgagggct tctgggtctat ttctgtgcaa gacggagac tacgacggta ggccgttatt acctactag 480 cggctctat ttctgtgcaa gacggagac tacgacggta ggccgttatt acctactaca 190 cagctggtg 200 cagcctggtg 200 cagctggtg 200 cagctggtg 200 cagcctggg 200 aggccgtggt ccagggtggt 200 aggctccagg 200 aggcccagg 200 aggccagga 200 aggccaga 200 aggccaga 200 aggc

```
gaaggggctg gagtggattg gatacataaa tcctagccgt ggttatacta attataatca 960
gaaggtgaag gaccgattca ccatctccag agacaactcc aagaacacgg cctttctgca 1020
aatggacagc ctgagacccg aggacacggg tgtgtatttc tgtgcgagat attatgatga 1080
tcattactqc cttqactatt qqqqccaqqq cacccqgtc accqtctcct cagtcqaagg 1140
tggaagtgga ggttctggtg gaagtggagg ttcaggtgga gtggacgaca tccagatgac 1200
ccaqtctcca tcctccctqt ctqcatctqt agqaqacaqa qtcaccatca cttqcaqaqc 1260
aagttcaagc gtaagctaca tgaattggta tcagcagaca ccagggaaag cccctaagag 1320
atggatctat gacacatcca aagtggcttc tggggtccca tcaaggttca gtggcagtgg 1380
atotgggaca gattacactt teaceateag eagtetgeaa eetgaagata ttgeaactta 1440
ctactgtcaa cagtggagta gtaaccetct cacttttggc caggggacca agctgcagat 1500
```

<210> 20

<211> 498

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic anti-CD3

<400> 20

Asp Ile Gln Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Leu Gly 5 10 1

Gln Arg Ala Thr Ile Ser Cys Lys Ala Ser Gln Ser Val Asp Tyr Asp 25

Gly Asp Ser Tyr Leu Asn Trp Tyr Gln Gln Ile Pro Gly Gln Pro Pro

Lys Leu Leu Ile Tyr Asp Ala Ser Asn Leu Val Ser Gly Ile Pro Pro 55

Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Asn Ile His

Pro Val Glu Lys Val Asp Ala Ala Thr Tyr His Cys Gln Gln Ser Thr 90

Glu Asp Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Gly 100

Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gln Val

Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro Gly Ser Ser Val 135 140

Asn Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile Gly Gln 165 170 175

Ile Trp Pro Gly Asp Gly Asp Thr Asn Tyr Asn Gly Lys Phe Lys Gly 180 185 190

Lys Ala Thr Leu Thr Ala Asp Glu Ser Ser Ser Thr Ala Tyr Met Gln 195 200 205

Leu Ser Ser Leu Ala Ser Glu Asp Ser Ala Val Tyr Phe Cys Ala Arg 210 215 220

Arg Glu Thr Thr Val Gly Arg Tyr Tyr Ala Met Asp Tyr Trp 225 230 235 240

Gly Gln Gly Thr Thr Val Thr Val Ser Ser Gly Gly Gly Ser Gln 245 250 255

Val Gln Leu Val Gln Ser Gly Gly Gly Val Val Gln Pro Gly Arg Ser  $260 \hspace{1.5cm} 265 \hspace{1.5cm} 270 \hspace{1.5cm}$ 

Leu Arg Leu Ser Cys Lys Ser Ser Gly Tyr Thr Phe Thr Arg Tyr Thr 275 280 285

Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile Gly 290 295 300

Tyr Ile Asn Pro Ser Arg Gly Tyr Thr Asn Tyr Asn Gln Lys Val Lys 305 310 315 320

Asp Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Ala Phe Leu 325 330 335

Gln Met Asp Ser Leu Arg Pro Glu Asp Thr Gly Val Tyr Phe Cys Ala 340 345 350

Arg Tyr Tyr Asp Asp His Tyr Cys Leu Asp Tyr Trp Gly Gln Gly Thr 355 360 365

Pro Val Thr Val Ser Ser Val Glu Gly Gly Ser Gly Gly Ser Gly Gly 370 375 380

Ser Gly Gly Ser Gly Gly Val Asp Asp Ile Gln Met Thr Gln Ser Pro 385 390 395 400

Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg 405 410 415

Ala Ser Ser Ser Val Ser Tyr Met Asn Trp Tyr Gln Gln Thr Pro Gly  $420 \hspace{1.5cm} 425 \hspace{1.5cm} 430$ 

Lys Ala Pro Lys Arg Trp Ile Tyr Asp Thr Ser Lys Val Ala Ser Gly 435 440 445

Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Thr Phe 450 460

Thr Ile Ser Ser Leu Gln Pro Glu Asp Ile Ala Thr Tyr Tyr Cys Gln 465 470 475 480

Gln Trp Ser Ser Asn Pro Leu Thr Phe Gly Gln Gly Thr Lys Leu Gln 485 490 495

Ile Thr

<210> 21

<211> 360

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
5-10 VH

<400> 21

gaggtgcagctgctcgagcagtctggagctgagctggtaaggcctgggacttcagtgaagatatcctgcaaggcttctggatacgccttcactaactactggctaggttgggtaaagcagaggcctggacatggacttgagtggattggagatattttccctggaagtggtaatatccactacaatgagaagttcaagggcaaagccacactgactgcagacaaatcttcgagcacagcctatatgcagctcagtagcctgacatttgaggactctgctgtctatttctgtgcaagactgaggaactggacgagcctatggactactggggccaagggaccacggtcaccgtctcctcc

<210> 22

<211> 120

<212> PRT

<213> Artificial Sequence

<223> Description of Artificial Sequence: Synthetic 5-10 VH <400> 22 Glu Val Gln Leu Leu Glu Gln Ser Gly Ala Glu Leu Val Arg Pro Gly Thr Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ala Phe Thr Asn 25 20 Tyr Trp Leu Gly Trp Val Lys Gln Arg Pro Gly His Gly Leu Glu Trp Ile Gly Asp Ile Phe Pro Gly Ser Gly Asn Ile His Tyr Asn Glu Lys Phe Lys Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala 70 75 Tyr Met Gln Leu Ser Ser Leu Thr Phe Glu Asp Ser Ala Val Tyr Phe 90 Cys Ala Arg Leu Arg Asn Trp Asp Glu Pro Met Asp Tyr Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 120 115 <210> 23 <211> 339 <212> DNA <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Synthetic 5-10 VL <400> 23 60 qaqctcqtqa tqacacaqtc tccatcctcc ctgactgtga cagcaggaga gaaggtcact atgagetgea agtecagtea gagtetgtta aacagtggaa atcaaaagaa etaettgace 120 180 tggtaccagc agaaaccagg gcagcctcct aaactgttga tctactgggc atccactagg 240 gaatctgggg tccctgatcg cttcacaggc agtggatctg gaacagattt cactctcacc

atcagcagtg tgcaggctga agacctggca gtttattact gtcagaatga ttatagttat

ccgctcacgt tcggtgctgg gaccaagctt gagatcaaa

300

339

```
<210> 24
<211> 113
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: Synthetic
      5-10 VL
<400> 24
Glu Leu Val Met Thr Gln Ser Pro Ser Ser Leu Thr Val Thr Ala Gly
                                    10
Glu Lys Val Thr Met Ser Cys Lys Ser Ser Gln Ser Leu Leu Asn Ser
Gly Asn Gln Lys Asn Tyr Leu Thr Trp Tyr Gln Gln Lys Pro Gly Gln
                            40
Pro Pro Lys Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val
                        5.5
Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr
                    70
Ile Ser Ser Val Gln Ala Glu Asp Leu Ala Val Tyr Tyr Cys Gln Asn
Asp Tyr Ser Tyr Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Ile
Lys
<210> 25
<211> 360
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: Synthetic
      3-1 VH
<400> 25
                                                                       60
gaggtgcagc tgctcgagca gtctggagct gagctggtga aacctggggc ctcagtgaag
atatectgea aggettetgg atacgeette actaactact ggetaggttg ggtaaageag
                                                                      120
                                                                      180
aggcctggac atggacttga gtggattgga gatcttttcc ctggaagtgg taatactcac
tacaatgaga ggttcagggg caaagccaca ctgactgcag acaaatcctc gagcacagcc
                                                                      240
tttatgcagc tcagtagcct gacatctgag gactctgctg tctatttctg tgcaagattg
                                                                      300
aggaactggg acgaggctat ggactactgg ggccaaggga ccacggtcac cgtctcctcc
                                                                      360
```

<210> 26 <211> 120 <212> PRT <213> Artificial Sequence <223> Description of Artificial Sequence: Synthetic 3-1 VH Glu Val Gln Leu Leu Glu Gln Ser Gly Ala Glu Leu Val Lys Pro Gly 10 Ala Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ala Phe Thr Asn Tyr Trp Leu Gly Trp Val Lys Gln Arg Pro Gly His Gly Leu Glu Trp 40 . 45 Ile Gly Asp Leu Phe Pro Gly Ser Gly Asn Thr His Tyr Asn Glu Arg Phe Arg Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala Phe Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe · 85 90 Cys Ala Arg Leu Arg Asn Trp Asp Glu Ala Met Asp Tyr Trp Gly Gln 105 Gly Thr Thr Val Thr Val Ser Ser 115 <210> 27 <211> 321 <212> DNA <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Synthetic 3-1 VL <400> 27 60 gagetegtea tgacecagte tecatettat ettgetgeat eteetggaga aaceattaet attaattgca gggcaagtaa gagcattagc aaatatttag cctggtatca agagaaacct 120 gggaaaacta ataagcttct tatctactct ggatccactt tgcaatctgg aattccatca 180 aggttcagtg gcagtggatc tggtacagat ttcactctca ccatcagtag cctggagcct 240 gaagattttg caatgtatta ctgtcaacag cataatgaat atccgtacac gttcggaggg 300 gggaccaagc ttgagatcaa a 321 <210> 28 <211> 107 <212> PRT <213> Artificial Sequence <223> Description of Artificial Sequence: Synthetic 3-1 VL Glu Leu Val Met Thr Gln Ser Pro Ser Tyr Leu Ala Ala Ser Pro Gly Glu Thr Ile Thr Ile Asn Cys Arg Ala Ser Lys Ser Ile Ser Lys Tyr Leu Ala Trp Tyr Gln Glu Lys Pro Gly Lys Thr Asn Lys Leu Leu Ile 45 40 Tyr Ser Gly Ser Thr Leu Gln Ser Gly Ile Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro Glu Asp Phe Ala Met Tyr Tyr Cys Gln Gln His Asn Glu Tyr Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 100 <210> 29 <211> 372 <212> DNA <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Synthetic 4-7 VH <400> 29 gaggtgcagc tgctcgagca gtctggagct gagctggcga ggcctggggc ttcagtgaag 60 ctgtcctgca aggcttctgg ctacaccttc acaaactatg gtttaagctg ggtgaagcag 120 180 aggcctggac aggtccttga gtggattgga gaggtttatc ctagaattgg taatgcttac 240 tacaatgaga agttcaaggg caaggccaca ctgactgcag acaaatcctc cagcacagcg tccatggagc tccgcagcct gacctctgag gactctgcgg tctatttctg tgcaagacgg 300 ggatcctacg atactaacta cgactggtac ttcgatgtct ggggccaagg gaccacggtc 360 accgtctcct cc 372

<210> 30

<211> 124

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic 4-7 VH

<400> 30

Glu Val Gl<br/>n Leu Glu Gl<br/>n Ser Gly Ala Glu Leu Ala Arg Pro Gly 1 5 10 15

Ala Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn 20 25 30

Tyr Gly Leu Ser Trp Val Lys Gln Arg Pro Gly Gln Val Leu Glu Trp 35 40 45

Ile Gly Glu Val Tyr Pro Arg Ile Gly Asn Ala Tyr Tyr Asn Glu Lys 50 55 60

Phe Lys Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala 65 70 75 80

Ser Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe 85 90 95

Cys Ala Arg Arg Gly Ser Tyr Asp Thr Asn Tyr Asp Trp Tyr Phe Asp 100 105 110

Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 115 120

<210> 31

<211> 336

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  $4-7~{
m VL}$ 

<400> 31

gagetegtga tgacceagae tecaetetee etgeetgtea gtettggaga teaageetee 60 atetettgea gatetagtea gageettgta cacagtaatg gaaacaceta tttacattgg 120 tacetgeaga ageeaggeea gtetecaaag etcetgatet acaaagttte caacegattt 180

tctggggtcc cagacaggtt cagtggcagt ggatcaggga cagatttcac actcaagatc agcagagtgg aggctgagga tctgggagtt tatttctgct ctcaaagtac acatgttccg tacacgttcg gagggggac caagcttgag atcaaa 336									
<210> 32 <211> 112 <212> PRT <213> Artificial Sequence									
<220> <223> Description of Artificial Se 4-7 VL	equence: Synthetic								
<400> 32 Glu Leu Val Met Thr Gln Thr Pro Le 1 5	eu Ser Leu Pro Val Ser Leu Gly 10 15								
Asp Gln Ala Ser Ile Ser Cys Arg Se 20 25									
Asn Gly Asn Thr Tyr Leu His Trp Ty 35 40	vr Leu Gln Lys Pro Gly Gln Ser 45								
Pro Lys Leu Leu Ile Tyr Lys Val Se 50 55	er Asn Arg Phe Ser Gly Val Pro 60								
Asp Arg Phe Ser Gly Ser Gly Ser Gl 65 70	y Thr Asp Phe Thr Leu Lys Ile 75 80								
Ser Arg Val Glu Ala Glu Asp Leu Gl 85	y Val Tyr Phe Cys Ser Gln Ser 90 95								
Thr His Val Pro Tyr Thr Phe Gly Gl									
<210> 33 <211> 1470 <212> DNA <213> Artificial Sequence									
<220> <223> Description of Artificial Sequence: Synthetic anti-CD3									
<400> 33 gagctcgtca tgacccagtc tccatcttat cttgctgcat ctcctggaga aaccattact 60 attaattgca gggcaagtaa gagcattagc aaatatttag cctggtatca agagaaacct 120 gggaaaacta ataagcttct tatctactct ggatccactt tgcaatctgg aattccatca 180 aggttcagtg gcagtggatc tggtacagat ttcactcta ccatcagtag cctggagcct 240 gaagattttg caatgtatta ctgtcaacag cataatgaat atccgtacac gttcggaggg 300									

```
19
                                                                      360
gggaccaagc ttgagatcaa aggtggtggt ggttctggcg gcggcggctc cggtggtggt
ggttctgagg tgcagctgct cgagcagtct ggagctgagc tggtgaaacc tggggcctca
                                                                      420
qtqaaqatat cctqcaaqqc ttctqqatac qccttcacta actactggct aggttgggta
                                                                      480
                                                                      540
aagcaqaqqc ctqqacatqq acttqaqtqq attqqaqatc ttttccctgq aagtggtaat
                                                                      600
actcactaca atgagaggtt caggggcaaa gccacactga ctgcagacaa atcctcgagc
acagccttta tgcagctcag tagcctgaca tctgaggact ctgctgtcta tttctgtgca
                                                                      660
agattgagga actgggacga ggctatggac tactggggcc aagggaccac ggtcaccgtc
                                                                      720
tcctccggag gtggtggatc ccaggtgcag ctggtgcagt ctgggggagg cgtggtccag
                                                                      780
cctgggaggt ccctgagact ctcctgtaag tcttctggat acaccttcac taggtatacg
                                                                      840
                                                                      900
atgcactqqq tccqccaqqc tccaqqqaaq qggctggagt ggattggata cataaatcct
                                                                      960
aqccqtqqtt atactaatta taatcagaag gtgaaggacc gattcaccat ctccagagac
                                                                     1020
aactccaaga acacggcctt tctgcaaatg gacagcctga gacccgagga cacgggtgtg
                                                                     1080
tatttctgtg cgagatatta tgatgatcat tactgccttg actattgggg ccagggcacc
ccggtcaccg tctcctcagt cgaaggtgga agtggaggtt ctggtggaag tggaggttca
                                                                     1140
ggtggagtgg acgacatcca gatgacccag tctccatcct ccctgtctgc atctgtagga
                                                                     1200
gacagagtca ccatcacttg cagagcaagt tcaagcgtaa gctacatgaa ttggtatcag
                                                                     1260
                                                                     1320
cagacaccag qqaaaqcccc taagagatgg atctatgaca catccaaagt ggcttctggg
                                                                     1380
qtcccatcaa qqttcaqtqq caqtqqatct qgqacaqatt acactttcac catcaqcaqt
ctgcaacctg aagatattgc aacttactac tgtcaacagt ggagtagtaa ccctctcact
                                                                     1440
                                                                     1470
tttggccagg ggaccaagct gcagatcacc
<210> 34
<211> 490
<212> PRT
<213> Artificial Sequence
<223> Description of Artificial Sequence: Synthetic
      anti-CD3
<400> 34
Glu Leu Val Met Thr Gln Ser Pro Ser Tyr Leu Ala Ala Ser Pro Gly
                                    10
```

Glu Thr Ile Thr Ile Asn Cys Arg Ala Ser Lys Ser Ile Ser Lys Tyr

Leu Ala Trp Tyr Gln Glu Lys Pro Gly Lys Thr Asn Lys Leu Leu Ile 40

Tyr Ser Gly Ser Thr Leu Gln Ser Gly Ile Pro Ser Arg Phe Ser Gly 50 55 60

Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro 75 80 65 70

Glu Asp Phe Ala Met Tyr Tyr Cys Gln Gln His Asn Glu Tyr Pro Tyr 85

Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Gly Gly Gly Ser 100 105

- Gly Gly Gly Ser Gly Gly Gly Ser Glu Val Gln Leu Leu Glu 115 120 125
- Gln Ser Gly Ala Glu Leu Val Lys Pro Gly Ala Ser Val Lys Ile Ser 130 135 140
- Cys Lys Ala Ser Gly Tyr Ala Phe Thr Asn Tyr Trp Leu Gly Trp Val 145 150 155 160
- Lys Gln Arg Pro Gly His Gly Leu Glu Trp Ile Gly Asp Leu Phe Pro 165 170 175
- Gly Ser Gly Asn Thr His Tyr Asn Glu Arg Phe Arg Gly Lys Ala Thr 180 185 190
- Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala Phe Met Gln Leu Ser Ser 195 200 205
- Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys Ala Arg Leu Arg Asn 210 215 220
- Trp Asp Glu Ala Met Asp Tyr Trp Gly Gln Gly Thr Thr Val Thr Val 225 230 235 240
- Ser Ser Gly Gly Gly Ser Gln Val Gln Leu Val Gln Ser Gly Gly 245 250 255
- Gly Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Lys Ser Ser 260 265 270
- Gly Tyr Thr Phe Thr Arg Tyr Thr Met His Trp Val Arg Gln Ala Pro 275 280 285
- Gly Lys Gly Leu Glu Trp Ile Gly Tyr Ile Asn Pro Ser Arg Gly Tyr 290 295 300
- Thr Asn Tyr Asn Gln Lys Val Lys Asp Arg Phe Thr Ile Ser Arg Asp 305 310 315 320
- Asn Ser Lys Asn Thr Ala Phe Leu Gln Met Asp Ser Leu Arg Pro Glu 325 330 335

Asp Thr Gly Val Tyr Phe Cys Ala Arg Tyr Tyr Asp Asp His Tyr Cys 340 345 350

Leu Asp Tyr Trp Gly Gln Gly Thr Pro Val Thr Val Ser Ser Val Glu 355 360 365

Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly Gly Val Asp 370 375 380

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 385 390 395 400

Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Ser Ser Val Ser Tyr Met 405 410 415

Asn Trp Tyr Gln Gln Thr Pro Gly Lys Ala Pro Lys Arg Trp Ile Tyr 420 425 430

Asp Thr Ser Lys Val Ala Ser Gly Val Pro Ser Arg Phe Ser Gly Ser 435 440 445

Gly Ser Gly Thr Asp Tyr Thr Phe Thr Ile Ser Ser Leu Gln Pro Glu 450 460

Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Trp Ser Ser Asn Pro Leu Thr 465 470 475 480

Phe Gly Gln Gly Thr Lys Leu Gln Ile Thr 485 490

<210> 35

<211> 1498

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
 anti-CD3

<400> 35

tgtacactcc gagctcgtga tgacacagtc tccatcctcc ctgactgta cagcaggaga 60 gaaggtcact atgagctgca agtccagtca gagtctgtta aacagtggaa atcaaaagaa 120 ctacttgacc tggtaccagc agaaaccagg gcagcctcct aaactgttga tctactgggc 180 atcactcacc atcagcagtg tgcaggctga agacctggca gtttattact gtcagaatga 300 ttatagttat ccgctcacgt tcggtgctgg gaccaagctt gagatcaaag gtggtggtgg 360 ttctggcgc gtgagctcg gtggtggtgg ttctgaggtg cagctgctcg agcagtctg 420 agctgagctg gtaaggctg ggacttcagt gagatatcc tgcaaggct ctggatacgc 480

```
cttcactaac tactggctag gttgggtaaa gcagaggcct ggacatggac ttgagtggat 540
tggagatatt ttccctggaa gtggtaatat ccactacaat gagaagttca agggcaaagc 600
cacactgact gcagacaaat cttcgagcac agcctatatg cagctcagta gcctgacatt 660
tgaggactet getgtetatt tetgtgeaag aetgaggaac tgggaegage etatggaeta 720
ctggggccaa gggaccacgg tcaccgtctc ctccggaggt ggtggctccc aggtgcagct 780
ggtgcagtct gggggaggcg tggtccagcc tgggaggtcc ctgagactct cctgtaagtc 840
ttctggatac accttcacta ggtatacgat gcactgggtc cgccaggctc cagggaaggg 900
gctggagtgg attggataca taaatcctag ccgtggttat actaattata atcagaaggt 960
gaaggaccga ttcaccatct ccagagacaa ctccaagaac acggcctttc tgcaaatgga 1020
cagcctgaga cccgaggaca cgggtgtgta tttctgtgcg agatattatg atgatcatta 1080
ctgccttgac tattggggcc agggcacccc ggtcaccgtc tcctcagtcg aaggtggaag 1140
tggaggttct ggtggaagtg gaggttcagg tggagtggac gacatccaga tgacccagtc 1200
tocatoctoc otgtotgoat otgtaggaga cagagtoaco atoactigoa gagcaagtto 1260
aagcgtaagc tacatgaatt ggtatcagca gacaccaggg aaagccccta agagatggat 1320
ctatqacaca tccaaaqtqq cttctqqqqt cccatcaaqq ttcaqtqqca gtggatctgg 1380
qacaqattac actttcacca tcagcagtct gcaacctgaa gatattgcaa cttactactg 1440
tcaacagtgg agtagtaacc ctctcacttt tggccagggg accaagctgc agatcacc
<210> 36
<211> 496
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: Synthetic
      anti-CD3
<400> 36
Glu Leu Val Met Thr Gln Ser Pro Ser Ser Leu Thr Val Thr Ala Gly
Glu Lys Val Thr Met Ser Cys Lys Ser Ser Gln Ser Leu Leu Asn Ser
            20
Gly Asn Gln Lys Asn Tyr Leu Thr Trp Tyr Gln Gln Lys Pro Gly Gln
                            40
Pro Pro Lys Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val
Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr
                    70
65
Ile Ser Ser Val Gln Ala Glu Asp Leu Ala Val Tyr Tyr Cys Gln Asn
                                    90
```

Asp Tyr Ser Tyr Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Ile

Lys Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser 115 120 125

Glu Val Gln Leu Leu Glu Gln Ser Gly Ala Glu Leu Val Arg Pro Gly 130 135 140

Thr Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ala Phe Thr Asn 145 150 155 160

Tyr Trp Leu Gly Trp Val Lys Gln Arg Pro Gly His Gly Leu Glu Trp 165 170 175

Ile Gly Asp Ile Phe Pro Gly Ser Gly Asn Ile His Tyr Asn Glu Lys
180 185 190

Phe Lys Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala 195 200 205

Tyr Met Gln Leu Ser Ser Leu Thr Phe Glu Asp Ser Ala Val Tyr Phe 210 215 220

Cys Ala Arg Leu Arg Asn Trp Asp Glu Pro Met Asp Tyr Trp Gly Gln 225 230 235 240

Gly Thr Thr Val Thr Val Ser Ser Gly Gly Gly Ser Gln Val Gln  $245_{\,\cdot\,}$  250 255

Leu Val Gl<br/>n Ser Gly Gly Gly Val Val Gl<br/>n Pro Gly Arg Ser Leu Arg 260 265 270

Leu Ser Cys Lys Ser Ser Gly Tyr Thr Phe Thr Arg Tyr Thr Met His 275 280 285

Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile Gly Tyr Ile 290 295 300

Asn Pro Ser Arg Gly Tyr Thr Asn Tyr Asn Gln Lys Val Lys Asp Arg 305 310 315 320

Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Ala Phe Leu Gln Met 325 330 335

Asp Ser Leu Arg Pro Glu Asp Thr Gly Val Tyr Phe Cys Ala Arg Tyr 340 345 350

Tyr Asp Asp His Tyr Cys Leu Asp Tyr Trp Gly Gln Gly Thr Pro Val 355 360 365

Thr Val Ser Ser Val Glu Gly Gly Ser Gly Gly Ser Gly Gly Ser Gly 370 \$375\$

Gly Ser Gly Gly Val Asp Asp Ile Gln Met Thr Gln Ser Pro Ser Ser 385 390 395 400

Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser 405 410 415

Ser Ser Val Ser Tyr Met Asn Trp Tyr Gln Gln Thr Pro Gly Lys Ala 420 425 430

Pro Lys Arg Trp Ile Tyr Asp Thr Ser Lys Val Ala Ser Gly Val Pro 435 440 445

Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Thr Phe Thr Ile 450 460

Ser Ser Leu Gln Pro Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Trp 465 470 475 480

Ser Ser Asn Pro Leu Thr Phe Gly Gln Gly Thr Lys Leu Gln Ile Thr 485 490 495

<210> 37

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
 peptide

<400> 37

Leu Glu Trp Ile Gly
1 5

<210> 38

<211> 10

<212> PRT

<213> Artificial Sequence

```
<220>
<223> Description of Artificial Sequence: Synthetic
     peptide
<400> 38
Ser Ala Ser Ser Ser Val Ser Tyr Met Asn
                 5
<210> 39
<211> 7
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: Synthetic
     peptide
<400> 39
Asp Thr Ser Lys Leu Ala Ser
              5
<210> 40
<211> 9
<212> PRT
<213> Artificial Sequence
<223> Description of Artificial Sequence: Synthetic
      peptide
<400> 40
Gln Gln Trp Ser Ser Asn Pro Phe Thr
```